Ardent Health Analysts Revise Forecasts Downward Following Disappointing Q3 Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy ARDT?
Source: Benzinga
Earnings Report: Ardent Health Inc reported a loss of 17 cents per share for Q3, missing the analyst estimate of 41 cents, while sales of $1.577 billion exceeded expectations of $1.547 billion.
Guidance Revision: The company lowered its FY2025 GAAP EPS guidance from a range of $1.73-$2.01 to $0.85-$1.03.
Operational Performance: Despite the earnings miss, Ardent Health saw a 5.8% increase in admissions and a 1.4% rise in total surgeries, with revenue and adjusted EBITDA growing by 9% and 46%, respectively.
Analyst Reactions: Following the earnings announcement, Morgan Stanley downgraded the stock from Overweight to Equal-Weight, reducing the price target from $22 to $12, while Stephens & Co. maintained an Overweight rating but lowered the target from $21 to $17.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARDT
Wall Street analysts forecast ARDT stock price to rise
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 9.780
Low
10.00
Averages
13.73
High
17.00
Current: 9.780
Low
10.00
Averages
13.73
High
17.00
About ARDT
Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ardent Health Shareholder Notice Issued
- False Financial Reporting: Ardent Health is accused of concealing the true state of its accounts receivable from July 18, 2024, to November 12, 2025, leading to materially misleading financial statements that adversely affected investor decisions and stock price.
- Insufficient Liability Insurance: The company failed to maintain adequate professional malpractice liability insurance to cover claims, particularly under increasing social inflation pressures in New Mexico, which could result in significant future liabilities and exacerbate financial risks.
- Shareholder Action Call: Shareholders are urged to register for the class action lawsuit by March 9, 2026, to potentially become lead plaintiffs, highlighting the lack of corporate governance and transparency that has put their investments at risk.
- Law Firm Involvement: The Gross Law Firm, a nationally recognized class action firm, is committed to protecting investor rights and emphasizes the need for companies to adhere to responsible business practices, ensuring that investors can seek compensation for losses incurred due to fraud and misleading statements.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors that class action lawsuits have been filed against companies including agilon health, Fermi Inc., Varonis Systems, and Ardent Health, with deadlines for lead plaintiff motions approaching.
- agilon health Allegations: From February 26 to August 4, 2025, agilon health is accused of making materially false statements regarding its financial guidance, failing to disclose industry headwinds, which misled investors about the company's prospects, with a lead plaintiff deadline of March 2, 2026.
- Fermi Inc. Lawsuit Details: Fermi Inc. is charged with overstating tenant demand and the reliance on a single tenant's funding for its Project Matador from October 1 to December 11, 2025, with a lead plaintiff deadline of March 6, 2026.
- Varonis and Ardent Issues: Varonis is accused of being ill-equipped to sustain its ARR growth from February 4 to October 28, 2025, while Ardent is charged with failing to accurately assess the collectability of accounts receivable from July 18, 2024, to November 12, 2025, with lead plaintiff deadlines of March 9, 2026, for both companies.
See More
Ardent Health Class Action Reminder for Investors
- Financial Decline: Ardent Health reported a $43 million revenue drop in Q3 2025, primarily due to negative revisions in the collectability of certain accounts receivable, leading to a 33.8% stock price plunge to $9.30 per share on November 13, 2025, which severely impacted investor confidence.
- Lawsuit Context: The class action lawsuit alleges that the company failed to disclose significant adverse facts regarding accounts receivable during the Class Period from July 18, 2024, to November 12, 2025, allowing investors until March 9, 2026, to apply as lead plaintiffs.
- Increased Liability Reserves: Ardent also reported a $54 million increase in professional liability reserves due to settlements and ongoing litigations in New Mexico, highlighting the financial risks posed by social inflation in medical malpractice claims, which further complicates the company's financial outlook.
- Investor Rights Protection: Investors who purchased Ardent securities during the Class Period can seek compensation through legal channels, indicating serious deficiencies in the company's transparency and compliance, which may affect future investor confidence.
See More
Class Action Securities Lawsuit Against Ardent Health, Inc.
- Lawsuit Background: Levi & Korsinsky LLP has notified investors of a class action lawsuit against Ardent Health, Inc. for alleged securities fraud, covering the period from July 18, 2024, to November 12, 2025, aimed at recovering losses for affected investors.
- Financial Misrepresentation: The complaint alleges that Ardent Health misrepresented the collectability of accounts receivable by employing a 180-day cliff for reserving uncollectible accounts, which resulted in a materially false financial position during the class period.
- Insurance Deficiency Issues: Ardent Health reportedly failed to maintain adequate professional liability insurance to cover claims arising from its operations, exposing the company to significant social inflationary pressures in the New Mexico market, thereby increasing financial risks.
- Investor Rights Protection: Affected investors have until March 9, 2026, to request to be appointed as lead plaintiff, with participation in the lawsuit at no cost, indicating a risk-free opportunity for investors to seek compensation.
See More
Ardent Health Investors Alert for Securities Class Action
- Deadline for Claims: Investors must file lead plaintiff applications for the securities class action against Ardent Health by March 9, 2026, if they purchased securities between July 18, 2024, and November 12, 2025, indicating significant legal exposure for the company.
- Financial Disclosure Impact: On November 12, 2025, Ardent disclosed a $43 million revenue decrease for Q3 2025, leading to a revised EBITDA guidance cut to $575 million, approximately a 9.6% drop, highlighting insufficient financial transparency under the new revenue accounting system.
- Stock Price Volatility: Following the financial disclosures, Ardent's stock price plummeted by $4.75, nearly 34%, from $14.05 to $9.30 per share on November 13, 2025, reflecting market concerns over the company's financial health and stability.
- Legal Liability Risks: Ardent and its executives face allegations of failing to disclose material information during the class period, violating federal securities laws, which could result in substantial liability and negatively impact future operations and investor confidence.
See More
Ardent Health Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Ardent Health (ARDT) in the U.S. District Court for the Middle District of Tennessee on behalf of investors who purchased securities between July 18, 2024, and November 12, 2025, indicating significant legal risks for the company.
- Financial Issues Exposed: The lawsuit alleges that Ardent Health delayed recognizing losses on uncollectible accounts receivable during the class period, resulting in a $43 million revenue decrease for Q3 2025, which directly impacts the company's financial health and credibility.
- Stock Price Volatility: Following the financial disclosures on November 12, 2025, Ardent Health's stock plummeted from $14.05 to $9.30 per share, a nearly 34% drop, reflecting severe market concerns regarding the company's financial transparency and management practices.
- Investor Rights Protection: Investors are urged to apply by March 9, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the potential long-term implications for investor confidence and market performance due to the ongoing legal challenges faced by the company.
See More
Ardent Health Shareholder Notice Issued
- False Financial Reporting: Ardent Health is accused of concealing the true state of its accounts receivable from July 18, 2024, to November 12, 2025, leading to materially misleading financial statements that adversely affected investor decisions and stock price.
- Insufficient Liability Insurance: The company failed to maintain adequate professional malpractice liability insurance to cover claims, particularly under increasing social inflation pressures in New Mexico, which could result in significant future liabilities and exacerbate financial risks.
- Shareholder Action Call: Shareholders are urged to register for the class action lawsuit by March 9, 2026, to potentially become lead plaintiffs, highlighting the lack of corporate governance and transparency that has put their investments at risk.
- Law Firm Involvement: The Gross Law Firm, a nationally recognized class action firm, is committed to protecting investor rights and emphasizes the need for companies to adhere to responsible business practices, ensuring that investors can seek compensation for losses incurred due to fraud and misleading statements.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors that class action lawsuits have been filed against companies including agilon health, Fermi Inc., Varonis Systems, and Ardent Health, with deadlines for lead plaintiff motions approaching.
- agilon health Allegations: From February 26 to August 4, 2025, agilon health is accused of making materially false statements regarding its financial guidance, failing to disclose industry headwinds, which misled investors about the company's prospects, with a lead plaintiff deadline of March 2, 2026.
- Fermi Inc. Lawsuit Details: Fermi Inc. is charged with overstating tenant demand and the reliance on a single tenant's funding for its Project Matador from October 1 to December 11, 2025, with a lead plaintiff deadline of March 6, 2026.
- Varonis and Ardent Issues: Varonis is accused of being ill-equipped to sustain its ARR growth from February 4 to October 28, 2025, while Ardent is charged with failing to accurately assess the collectability of accounts receivable from July 18, 2024, to November 12, 2025, with lead plaintiff deadlines of March 9, 2026, for both companies.
See More
Ardent Health Class Action Reminder for Investors
- Financial Decline: Ardent Health reported a $43 million revenue drop in Q3 2025, primarily due to negative revisions in the collectability of certain accounts receivable, leading to a 33.8% stock price plunge to $9.30 per share on November 13, 2025, which severely impacted investor confidence.
- Lawsuit Context: The class action lawsuit alleges that the company failed to disclose significant adverse facts regarding accounts receivable during the Class Period from July 18, 2024, to November 12, 2025, allowing investors until March 9, 2026, to apply as lead plaintiffs.
- Increased Liability Reserves: Ardent also reported a $54 million increase in professional liability reserves due to settlements and ongoing litigations in New Mexico, highlighting the financial risks posed by social inflation in medical malpractice claims, which further complicates the company's financial outlook.
- Investor Rights Protection: Investors who purchased Ardent securities during the Class Period can seek compensation through legal channels, indicating serious deficiencies in the company's transparency and compliance, which may affect future investor confidence.
See More
Class Action Securities Lawsuit Against Ardent Health, Inc.
- Lawsuit Background: Levi & Korsinsky LLP has notified investors of a class action lawsuit against Ardent Health, Inc. for alleged securities fraud, covering the period from July 18, 2024, to November 12, 2025, aimed at recovering losses for affected investors.
- Financial Misrepresentation: The complaint alleges that Ardent Health misrepresented the collectability of accounts receivable by employing a 180-day cliff for reserving uncollectible accounts, which resulted in a materially false financial position during the class period.
- Insurance Deficiency Issues: Ardent Health reportedly failed to maintain adequate professional liability insurance to cover claims arising from its operations, exposing the company to significant social inflationary pressures in the New Mexico market, thereby increasing financial risks.
- Investor Rights Protection: Affected investors have until March 9, 2026, to request to be appointed as lead plaintiff, with participation in the lawsuit at no cost, indicating a risk-free opportunity for investors to seek compensation.
See More
Ardent Health Investors Alert for Securities Class Action
- Deadline for Claims: Investors must file lead plaintiff applications for the securities class action against Ardent Health by March 9, 2026, if they purchased securities between July 18, 2024, and November 12, 2025, indicating significant legal exposure for the company.
- Financial Disclosure Impact: On November 12, 2025, Ardent disclosed a $43 million revenue decrease for Q3 2025, leading to a revised EBITDA guidance cut to $575 million, approximately a 9.6% drop, highlighting insufficient financial transparency under the new revenue accounting system.
- Stock Price Volatility: Following the financial disclosures, Ardent's stock price plummeted by $4.75, nearly 34%, from $14.05 to $9.30 per share on November 13, 2025, reflecting market concerns over the company's financial health and stability.
- Legal Liability Risks: Ardent and its executives face allegations of failing to disclose material information during the class period, violating federal securities laws, which could result in substantial liability and negatively impact future operations and investor confidence.
See More
Ardent Health Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Ardent Health (ARDT) in the U.S. District Court for the Middle District of Tennessee on behalf of investors who purchased securities between July 18, 2024, and November 12, 2025, indicating significant legal risks for the company.
- Financial Issues Exposed: The lawsuit alleges that Ardent Health delayed recognizing losses on uncollectible accounts receivable during the class period, resulting in a $43 million revenue decrease for Q3 2025, which directly impacts the company's financial health and credibility.
- Stock Price Volatility: Following the financial disclosures on November 12, 2025, Ardent Health's stock plummeted from $14.05 to $9.30 per share, a nearly 34% drop, reflecting severe market concerns regarding the company's financial transparency and management practices.
- Investor Rights Protection: Investors are urged to apply by March 9, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the potential long-term implications for investor confidence and market performance due to the ongoing legal challenges faced by the company.
See More
